|
|
|
|
|
|
|
Poster: 252
Visits: 25
Title: Baseline metabolic tumor burden in DLBCL affects response to immuno-chemotherapy and patients outcome through influence of rituximab pharmacokinetics. A LYSA group study.
Authors: Olivier Casasnovas ,
Centre: CHU Le Bocage, Dijon, France
|
|
You must be registered to reply or comment.
|
|
BASELINE METABOLIC TUMOR BURDEN IN DLBCL AFFECTS RESPONSE TO IMMUNO-CHEMOTHERAPY AND PATIENTS OUTCOME THROUGH INFLUENCE OF RITUXIMAB PHARMACOKINETICS. A LYSA GROUP STUDY.
|
|
You must be registered to reply or comment. |
|
|
|
|
|
|
Most viewed poster for this congress |
|
|
Poster: 9
Visits: 649
Title: Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial
Authors: Michael Wang ,
Centre: The University of Texas MD Anderson Cancer Center
|
|
|
|
|
|
|
Poster most viewed in this topic |
|
|
Poster: 154
Visits: 188
Title: NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy
Authors: Alexander Deutsch ,
Centre: Clinical Devision of Hematology
|
|
|
|